Claims for Patent: RE37525

Summary for Patent: RE37525

Title:	Method for treating infectious respiratory diseases
Abstract:	A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.
Inventor(s):	Prince; Gregory A. (Potomac, MD), Hemming; Val G. (Gaithersburg, MD)
Assignee:	Henry M. Jackson Foundation (Rockville, MD)
Application Number:	08/608,313
Patent Claims:	1. A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by a microorganism selected from a virus, a bacterium, a fungus, and Pneumocystis carinii, comprising administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 .mu.g to 1000 mg/kg body weight of the host to reduce inflammation and an anti-infectious agent with activity against said microorganism at a dosage of from 0.1 .mu.g to 1000 mg/kg body weight of the host to reduce the concentration of said microorganism; the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns..]..[. 2. The method of claim 1, wherein the anti-infectious agent is administered topically, orally, intravenously, or intraperitoneally..]..[. 3. The method of claim 1, wherein the anti-inflammatory agent is a corticosteroid..]..[. 4. The method of claim 3, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, triamcinolone, dexamethasone, and beclamethasone..]..[. 5. The method of claim 1, wherein the anti-inflammatory agent is administered intranasally..]..[. 6. The method of claim 1, wherein the microorganism is influenza virus type A, influenza virus type B, influenza virus type C, parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, a respiratory coronavirus, or a respiratory adenovirus..]..[. 7. The method of claim 1, wherein the microorganism is parainfluenza virus type 3, respiratory syncytial virus, or adenovirus type 5..]..[. 8. The method of claim 1, wherein the anti-infectious agent is an antibody to said microorganism..]..[. 9. The method of claim 8, wherein the antibody is a polyclonal or monoclonal antibody..]..[. 10. The method of claim 1, wherein the anti-infectious agent is human immunoglobulin which comprises antibodies to said microorganism..]..[. 11. The method of claim 10, wherein said human immunoglobulin is human immunoglobulin G is a dosage of from 0.1 .mu.g to 100 mg/kg body weight of the host..]..[. 12. The method of claim 10, wherein said microorganism is respiratory syncytial virus or parainfluenza virus type 3..]..[. 13. The method of claim 1, wherein the anti-infectious agent is an anti-bacterial agent, antifungal agent, anti-parasitic agent, or anti-viral agent..]..[. 14. The method of claim 1, wherein the anti-infectious agent is an anti-viral agent selected from the group consisting of ribavirin and amantidine..]..[. 15. The method of claim 1, wherein the host is a mammal..]..[. 16. The method of claim 1, wherein the host is a human..]. 17. A method of treating .Iadd.infectious .Iaddend.pneumonia .Iadd.and infectious bronchiolitis .Iaddend.in a human .Iadd.host, .Iaddend.susceptible to or suffering from pneumonia .Iadd.or bronchiolitis .Iaddend.caused by respiratory syncytial virus or parainfluenza virus type 3, comprising .Iadd.concurrently .Iaddend.administering .[.directly.]. into the lower respiratory tract of the .[.human.]. .Iadd.host .Iaddend.an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 .mu.g to 1000 mg/kg body weight of the host to reduce inflammation and .[.an.]. .Iadd.a .Iaddend.human immunoglobulin G at a dosage of from 0.1 .mu.g to 100 mg/kg body weight of the host to reduce the concentration of the respiratory syncytial virus or parainfluenza virus type 3, the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns. 18. The method of claim 17, wherein the anti-inflammatory agent is a corticosteroid..[. 19. A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by parainfluenza virus type 3, adenovirus type 5, or respiratory syncytial virus, comprising administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 .mu.g to 1000 mg/kg body weight of the host to reduce inflammation and an anti-infectious agent with activity against said virus at a dosage of from 0.1 .mu.g to 1000 mg/kg body weight of the host to reduce the concentration of said virus, the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns..]..[. 20. A medication that comprises aerosol particles having a size of less than 10 microns comprising an anti-infectious agent with activity against an infectious agent at a dosage of from 0.1 .mu.g to 1000 mg/kg body weight of a host to reduce the concentration of said infectious agent and an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 .mu.g to 1000 mg/kg weight of the host to reduce inflammation..]..[. 21. The method of claim 1 wherein the anti-inflammatory agent is administered at a dosage of 2 .mu.g to 0.2 mg/kg and the anti-infectious agent is administered at a dosage of 2 .mu.g to 200 mg/kg..]. 22. A method of treating .Iadd.infectious .Iaddend.pneumonia .Iadd.and infectious bronchiolitis .Iaddend.in a .Iadd.mammalian .Iaddend.host, susceptible to or suffering from pneumonia .Iadd.or bronchiolitis .Iaddend.caused by .[.a microorganism selected from a virus, a bacterium, a fungus, and Pneumocystis carinii.]. .Iadd.an infectious agent selected from the group consisting of influenza virus type A, influenza virus type B, influenza virus type C, parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, respiratory coronavirus, respiratory adenovirus, Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Klebsiella, Legionella, Coccidiodes immitus, Histoplasma capsulatum, Cryptococcus neoformans, Pneumocystis carnii, and rickettsia .Iaddend.comprising topically .Iadd.concurrently .Iaddend.administering .[.directly.]. into the lower respiratory tract of the host an anti-inflammatory agent .[.selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid.]. at a dosage of from .[.0.1 82 g.]. .Iadd.0.1 .mu.g .Iaddend.to 1000 mg/kg body weight of the host to reduce inflammation and an human immunoglobulin G at a dosage of from 0.1 .mu.g to 100 mg/kg body weight of the host to reduce the concentration of said infectious agent, microorganism, the anti-inflammatory agent and the human immunoglobulin G being administered in the form of a small particle aerosol having a size less than 10 microns..Iadd. 23. The method of claim 17, wherein the anti-inflammatory agent is selected from the group consisting of a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid..Iaddend..Iadd. 24. The method of claim 22, wherein the anti-inflammatory agent is selected from the group consisting of a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid..Iaddend.

Details for Patent RE37525

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000		2011-05-01
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2011-05-01
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2011-05-01
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007		2011-05-01
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009		2011-05-01
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	02/07/2013		2011-05-01